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Abstract
Disruption of 14-3-3 function by alpha-synuclein has been implicated in Parkinson’s disease. As 14-3-3s are important
regulators of cell death pathways, disruption of 14-3-3s could result in the release of pro-apoptotic factors, such as Bax. We
have previously shown that overexpression of 14-3-3h reduces cell loss in response to rotenone and MPP
+ in dopaminergic
cell culture and reduces cell loss in transgenic C. elegans that overexpress alpha-synuclein. In this study, we investigate the
mechanism for 14-3-3h’s neuroprotection against rotenone toxicity. While 14-3-3s can inhibit many pro-apoptotic factors,
we demonstrate that inhibition of one factor in particular, Bax, is important to 14-3-3s’ protection against rotenone toxicity
in dopaminergic cells. We found that 14-3-3h overexpression reduced Bax activation and downstream signaling events,
including cytochrome C release and caspase 3 activation. Pharmacological inhibition or shRNA knockdown of Bax provided
protection against rotenone, comparable to 14-3-3h’s neuroprotective effects. A 14-3-3h mutant incapable of binding Bax
failed to protect against rotenone. These data suggest that 14-3-3h’s neuroprotective effects against rotenone are at least
partially mediated by Bax inhibition and point to a potential therapeutic role of 14-3-3s in Parkinson’s disease.
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Introduction
Disruption of 14-3-3 expression and function has been implicated
in the pathogenesis of Parkinson’s disease (PD). This highly
conserved protein family, which includes seven isoforms in
mammals, are key regulators of cell death [1]. 14-3-3 proteins form
homo- and heterodimers that create a concave groove in which
ligands bind [2,3]. Upon ligand binding, 14-3-3s can alter the
conformational state of the ligand to alter activity or can bring
together two ligands to interact [2,3]. 14-3-3 ligands are implicated
in many cellular functions, including transcription, metabolism, and
apoptosis [2,3]. In general, 14-3-3 isoforms act to promote cell
survivalthroughinhibitionofmanyknownpro-apoptoticfactors[1].
In PD, several 14-3-3 isoforms – 14-3-3e, c, h, and f – colocalize
with the protein alpha-synuclein (a-syn) in Lewy bodies [4,5].
Although its mechanism of toxicity is unclear, a-syn plays a central
role in PD [6,7,8,9,10,11], and the amount of 14-3-3s that
coimmunoprecipitates with a-syn is increased in PD brains [12].
We have previously shown that the expression of several 14-3-3
isoforms is decreased in the brains of transgenic mice that
overexpress wildtype human a-syn [13,14]. Because of 14-3-3s’
anti-apoptotic role, we have hypothesized that disruption of 14-3-
3s by a-syn in PD could lead to the activation of pro-apoptotic
pathways that are normally inhibited by 14-3-3s. In support of this
hypothesis, we have shown that overexpression of 14-3-3h, e,o rc
reduced cell loss in response to rotenone and MPP
+ in
dopaminergic cell culture, while other isoforms showed variable
effects [14]. Human 14-3-3h and the C. elegans 14-3-3 homologue
ftt-2 also reduced cell loss in transgenic C. elegans that overexpress
a-syn [14]. The mechanism by which 14-3-3s are neuroprotective
has not been examined in these PD models.
14-3-3s’ effect on cell survival is thought to be mediated by their
ability to inhibit pro-apoptotic factors. 14-3-3s have been
demonstrated to bind and inhibit several different apoptotic
factors, including BAD, Bax, and Bim [1,15,16,17,18]. Bax is an
essential component in the apoptotic cascade, and its activation is
induced by rotenone and MPTP, neurotoxins that are used to
produce animal models of PD [19,20,21,22]. In the pro-survival
state, Bax is thought to be retained in the cytosol by binding to 14-
3-3s. In response to pro-apoptotic signals, Bax can become
dissociated from 14-3-3s and then be translocated to the
mitochondria [16,17,23]. Similarly, other pro-apoptotic factors,
such as BAD, can be bound by 14-3-3s to prevent the activation of
apoptosis [24].
Here we investigate whether inhibition of Bax plays a role in 14-
3-3s’ neuroprotective effect against rotenone. Because the theta
isoform showed the most substantial and consistent neuroprotec-
tion in our previous experiments, we focused on this isoform for
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activation is inhibited when 14-3-3h is overexpressed. Preventing
Bax activation by alternative means imparts similar reduction in
rotenone-induced cell death as 14-3-3h overexpression, and
disruption of 14-3-3h’s ability to bind Bax eliminates its protection
against rotenone toxicity. These findings suggest that inhibition of
Bax is key to 14-3-3h’s neuroprotective effects against rotenone.
Methods
14-3-3h cell lines
Full-length 14-3-3h was subcloned into the expression vector
pcDNA3.1/V5-His-TOPO (Invitrogen, Carlsbad, CA). C-termi-
nally deleted 14-3-3h (amino acids 1-239) was created by
subcloning the DNA fragment representing amino acids 1 to
239 by PCR (forward primer 59 caccgatcaaagtggtgggactcg; reverse
primer 59 cgcatcacattcttctcctg) into the expression vector
pcDNA3.1D/V5-His-TOPO (Invitrogen). Both full-length and
mutant 14-3-3h were tagged with V5-His at the C-terminal end.
SK-N-BE(2)-M17 (M17) cells (ATCC, Manassas, VA) were
transfected with these constructs using Superfect (Qiagen,
Germantown, MD), and stably-transfected cells were selected for
in the presence of G418 (500 mg/ml; Invitrogen). Experimental
controls included M17 cells transfected with the empty
pcDNA3.1/V5-His vector and selected for stable transfection in
the presence of G418.
Immunoprecipitation
Control, 14-3-3h, or 14-3-3h mutant cell lysates were sonicated
for 15 seconds on ice in lysis buffer [150 mM NaCl, 10 mM Tris-
HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, protease and
phosphatase inhibitor cocktail (Roche Diagnostics, Indianapolis,
IN), 0.5% NP-40] and centrifuged at 14000 g for 10 minutes.
Protein concentrations were determined by the bicinchoninic acid
assay (Pierce, Rockford, IL). Lysates were precleared with Protein
G Sepharose (Invitrogen) for one hour, and then incubated
overnight at 4C with 2 mg of a rabbit polyclonal antibody against
Bax (Cell Signaling, Danvers, MA) or rabbit IgG (Cell Signaling).
After a 3 hour incubation of the antibody-lysate mix with Protein
G Sepharose beads that had been preincubated with bovine serum
albumin, Sepharose beads were washed in lysis buffer five times
and then boiled for five minutes in 4xDTT sample loading buffer
(0.25 M Tris-HCl, pH 6.8, 8% SDS, 200 mM DTT, 30%
glycerol, bromophenol blue). Immunoprecipitate samples were
analyzed by Western blotting.
Subfractionation
Controland 14-3-3h cells were resuspended into cavitationbuffer
(5 mM HEPES, pH 7.4, 3 mM MgCl2, 1 mM EGTA, 250 mM
sucrose). Cells were then fractionated and mitochondria were
isolated as previously described with minor modifications [25].
Briefly, cells were disrupted by nitrogen cavitation (250 psi) for five
minutes on ice. After centrifugation of the resulting cell lysate at
5000 g for five minutes, the supernatant fraction was saved for
preparation of the cytosolic fraction, while the pellet was saved for
preparation of the mitochondrial fraction. The cytosolic fraction
was obtained by centrifugation of the supernatant at 100000 g for
one hour and concentration of the resulting supernatant using a
SpeedVac concentrator. To obtain the mitochondrial fraction, the
pellet from the initial centrifugation at 5000 g was resuspended in
cavitation buffer and layered over a discontinuous 1.0/1.5M
sucrose gradient prior to being centrifuged at 100000 g for 30
minutes at 4C. A hazy ring corresponding to the mitochondrial
fraction was carefully recovered from the interface between the two
sucrose solutions and diluted 1:2 in 5 mM HEPES (pH 7.4), 3 mM
MgCl2, and 1 mM EGTA prior to centrifugation at 20000 g for ten
minutes at 4C. The resulting pellet was washed several times in
cavitation buffer without sucrose, and then resuspended and
sonicated in lysis buffer (175 mM NaCl, 50 mM Tris-HCl,
pH 7.4, 5 mM EDTA, protease and phosphatase inhibitor cocktail,
1% Triton X-100). The resulting fractions were examined for Bax
and cytochrome C by Western blotting.
Bax oligomerization assay
Control and 14-3-3h cells were collected in cavitation buffer and
then disrupted by nitrogen cavitation (250 psi for 5 minutes) at 4C.
The resulting cellular lysates were centrifugated at 300 g for three
minutes at 4C to remove cellular debris. The resulting supernatant
was centrifuged at 21000 g for 10 minutes at 4C. The
mitochondrial-enriched pellet was washed three times in cavitation
buffer and then solubilized in 2% CHAPS buffer for one hour at
4C. This mitochondrial-enriched sample was then crosslinked with
1 mM ethylene-glycol-bis(succinic acid N-hydroxy-succinimide
ester) (Sigma) for 30 minutes at room temperature as previously
described [26]. Protein samples were analyzed for Bax monomers
and oligomers by Western blotting using a polyclonal antibody
against Bax.
Western Blot
Protein samples were resolved on 15% SDS-polyacrylamide gels
and transferred to PVDF or nitrocellulose membranes. Blots were
blocked in 5% non-fat dry milk in TBST (25 mM Tris-HCl,
pH 7.6, 137 mM NaCl, 0.1% Tween-20) for one hour, and then
incubated overnight with primary mouse monoclonal antibody
against 14-3-3h (1:1000; Abcam, #ab10439, Cambridge, MA),
rabbit polyclonal antibody against Bax (1:1000; Cell Signaling,
#2772), mouse monoclonal antibody against cytochrome C
(1:1000; Thermo Scientific, #MS-1192, Fremont, CA), rabbit
polyclonal antibody against cleaved caspase 3 (1:1000; Cell
Signaling, #9661), mouse monoclonal antibody against cyclophi-
lin D (1:7500; EMD Biosciences, #AP1035, Gibbstown, NJ),
mouse monoclonal antibody against the V5 epitope (1:5000;
Invitrogen, #R960), or mouse monoclonal antibody against a-
tubulin (1:1000; Sigma-Aldrich, #T9026, St. Louis, MO). After
three washes in Tris-buffered saline with 0.1% Tween-20 (TBST),
blots were incubated with HRP-conjugated goat anti-mouse or
anti-rabbit secondary antibody (Jackson ImmunoResearch, West
Grove, PA) for two hours and then washed in TBST six times for
ten minutes each. Immunoreactive proteins were detecting using
the enhanced chemiluminescence method (Pierce). Immunoblots
were quantified using densitometry (Un-Scan-It Automated
Digitizing System, Silk Scientific, Orem, UT).
Immunocytochemistry
Cells were fixed in 2% paraformaldehyde for 15 minutes,
washed in Tris-buffered saline (TBS), and incubated in 0.2%
CHAPS buffer for 30 minutes. After an hour incubation in
blocking buffer (2% goat serum, 3% bovine serum albumin in
TBS), cells were incubated with the 6A7 mouse monoclonal
antibody against Bax (1:1500; Sigma-Aldrich, #B8429) overnight
at 4C. After several washes in TBS, cells were incubated with a
secondary Alexa 488-conjugated goat anti-mouse antibody
(Invitrogen) for two hours at room temperature. After three
washes in TBS, cells were incubated with 1 mg/ml Hoechst 33342
(Invitrogen) for five minutes, rinsed in TBS, and then mounted in
Vectashield (Vector Laboratories, Burlingame, CA). Cells were
imaged using a Nikon Eclipse E800 epifluorescence microscope,
and images were captured with a Spot Flex CCD camera
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(20X) fields per well were randomly selected for quantification,
and the number of 6A7-positive cells and the total number of cells
stained by Hoechst 33342 were counted per high power field with
the rater blind to experimental conditions. Four wells per
condition were stained in each experiment, with a total of two
independent experiments.
JC-1 assay
Mitochondrial membrane potential (Dym) was determined
using the fluorescent dye 5,5,6,6-tetrachloro-1,1,3,3-tetraethylben-
zimidazolyl-carbocyanine iodide (JC-1), which is able to enter
mitochondria selectively [27]. JC-1 exists as a monomer emitting
at 528 nm after excitation at 485 nm; however, depending on the
Dym, JC-1 is able to form aggregates that are associated with a
large shift in emission (590 nm) after excitation at 530 nm. The
color of JC-1 changes from green to red as the mitochondrial
membrane becomes more polarized. The ratio of JC-1 aggregates
to monomers is independent of cell number or mitochondrial
density, such that quantification of the fluorescent state of JC-1 is a
direct indicator of the relative mitochondrial potential. Cell
staining was performed as follows: cells were plated in 24-well
plates and treated with rotenone (Sigma-Aldrich) at varying
concentrations. After drug treatment, cells were incubated with
5 mg/ml JC-1 for 30 minutes at 37C. After washing cells twice
with PBS, fluorescence was measured using a fluorescent plate
reader (Bio-Tek Synergy HT, Winooski, VT) set at excitation
485 nm and emission 528 nm for the green monomer, and at
excitation 530 nm and emission 590 nm for the red aggregates.
The ratio of JC-1 fluorescence (590 nm/ 528 nm) was calculated
as a direct measure of Dym.
LDH assay
Cells were grown in pyruvate-free DMEM for a few days prior
to plating in 24-well collagen-treated plates. Following treatment
with rotenone in serum-free DMEM for 48 hours, toxicity was
assayed by lactate dehydrogenase (LDH) release into media using
the LDH cytotoxicity kit (Roche). LDH release into media was
normalized to maximal LDH release for each well.
Statistical analysis
GraphPad Prism 5 (La Jolla, CA) was used for statistical analysis
of experiments. Western blots, 6A7 immunostaining, JC-1 assay,
and LDH assay experiments were analyzed by 2-way ANOVA,
followed by post-hoc Bonferroni’s multiple comparison test. For
the Bax subfractionation experiment, Bax expression level for
rotenone-treated cells was normalized to Bax expression level for
corresponding untreated cells. Normalized Bax levels were
analyzed by one sample t-test.
Results
14-3-3h immunoprecipitates with Bax
We have previously shown that overexpression of 14-3-3h in the
dopamine-producing cell line SK-N-BE(2)-M17 (M17) reduces cell
death induced by the neurotoxin rotenone [14]. To investigate
whether Bax inhibition may play a role in 14-3-3h’s neuroprotective
effects, we first examined whether 14-3-3h can immunoprecipitate
with Bax in M17 cells. After immunoprecipitation of lysates from
control M17 cells with a polyclonal antibody against Bax or rabbit
IgG, immunoprecipitates were immunoblotted with a monoclo-
nal antibody against 14-3-3h. Immunoprecipitation revealed that
14-3-3h did interact specifically with Bax in control cells (Fig. 1a).
We next examined whether 14-3-3h immunoprecipitated with Bax
in M17 cells that stably overexpressed 14-3-3h tagged with V5-His.
Lysates from vector control and 14-3-3h cells were immunoprecip-
itated with an anti-Bax antibody and then immunoblotted with an
anti-14-3-3h antibody. Endogenous 14-3-3h (Fig. 1b; lower band
around 30 kD, arrow) was immunoprecipitated with Bax in both
vector control and 14-3-3h stable cells, while exogenous, tagged 14-
3-3h was immunoprecipitated with Bax only in 14-3-3h stable cells
(Fig. 1b; higher band around 35 kD, arrowhead). Thus, 14-3-3h
immunoprecipitates with Bax, and overexpression of 14-3-3h results
in an increase of its association with Bax.
14-3-3h overexpression reduces Bax activation
Since 14-3-3h interacts with Bax as demonstrated by immuno-
precipitation, we hypothesized that increased binding of Bax in the
presence of higher 14-3-3h levels could reduce Bax activation. In
Figure 1. 14-3-3h immunoprecipitates with Bax in M17
dopaminergic cells. a) Cell lysates from M17 cells were immunopre-
cipitated with a polyclonal rabbit antibody against Bax or rabbit IgG,
and resulting immunoprecipitants were blotted with a monoclonal
mouse antibody against 14-3-3h in top blot. Lysate lane on right is
shown at a different exposure time than the immunoprecipitant lanes
from the same gel. Blot was reprobed with anti-Bax antibody to verify
Bax pulldown (bottom blot). 14-3-3h shows specific immunoprecipita-
tion with Bax. b) Cell lysates from M17 cells stably transfected with
empty vector or 14-3-3h tagged with the V5 epitope tag were
immunoprecipitated with a polyclonal antibody against Bax and then
immunoblotted against 14-3-3h. Both endogenous 14-3-3h (lower band
marked by arrow) and exogenous, tagged 14-3-3h (higher band marked
by arrowhead) were immunoprecipitated with Bax from cells overex-
pressing 14-3-3h, and the total amount of 14-3-3h immunoprecipitated
was increased in 14-3-3h cells compared to empty vector control cells.
Lysate lanes on right were run on a separate gel from the
immunoprecipitant lanes. Blot was reprobed with anti-Bax antibody
to verify pulldown of Bax (bottom blot).
doi:10.1371/journal.pone.0021720.g001
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alterations and translocates to the mitochondrial outer membrane,
where it undergoes oligomerization that leads to pore formation
[28,29]. We first tested whether 14-3-3h overexpression altered the
translocation of Bax into the mitochondria in response to
rotenone. Control and 14-3-3h stable cells were treated with
5 mM rotenone for approximately 24 hours, and then cell lysates
were fractionated into cytosolic and mitochondrial fractions. For
vector control cells treated with rotenone, immunoblotting of these
fractions showed that Bax levels decreased to 48% of untreated
cells in the cytosolic fraction (p,0.01, one sample t-test) and
increased to 194% of untreated cells in the mitochondrial fraction
(p,0.05, one sample t-test); this suggests that Bax translocates to
the mitochondria upon rotenone treatment (Fig. 2a). In contrast,
incubation of 14-3-3h cells with rotenone did not result in
significant changes in the cytosolic or mitochondrial Bax levels as
determined by Western blotting (Fig. 2a). Levels of total Bax
protein were similar in control and 14-3-3h cell lines and were not
affected by rotenone treatment in both cell lines, as determined by
Western blotting of whole cell lysates (Fig. 2b).
We next examined whether rotenone induced Bax conforma-
tional changes and whether these changes were altered in the
presence of 14-3-3h overexpression. We did immunocytochemistry
against activated Bax using the monoclonal antibody 6A7 that
detects an N-terminal Bax epitope that is exposed only upon Bax
activation [30,31]. Vector control and 14-3-3h stable cells were
incubated in the absence or presence of 1 or 5 mM rotenone for
24 hours, and then cells were fixed and stained with the 6A7
antibody. As seen in Fig. 2c, the numbers of 6A7-positive cells
increased with rotenone treatment in vector control cells, but this
increase was significantly attenuated in 14-3-3h cells (p,0.01 at
1 mM, p,0.001 at 5 mM, Bonferroni’s multiple comparison test).
We then tested whether the formation of Bax oligomers is
affected by 14-3-3h overexpression. Vector control and 14-3-3h
cells were treated with 5 mM rotenone for 24 hours, and then
mitochondrial-enriched cell lysates were crosslinked with 1 mM
ethylene-glycol-bis(succinic acid N-hydroxy-succinimide ester), as
previously described [26]. After crosslinking, lysates were run on a
gel and immunoblotted with an antibody against Bax to detect
monomers and oligomers of Bax. As seen in Fig. 2d, rotenone
induced oligomerization of Bax in vector control cells, while 14-3-
3h cells showed a reduced level of Bax oligomers in response to
rotenone treatment. The rotenone-mediated Bax dimer formation
in 14-3-3h cells was 15% of that in vector control cells treated with
rotenone (p,0.001, Bonferroni’s multiple comparison test).
Therefore, Bax activation is reduced upon rotenone treatment in
14-3-3h cells, as determined by decreased translocation, confor-
mational change, and oligomerization.
14-3-3h overexpression reduces signaling events
downstream of Bax activation
We next investigated whether apoptotic signaling events
downstream of Bax were altered in 14-3-3h cells upon rotenone
treatment. Upon activation and oligomerization, Bax causes
permeabilization of the outer mitochondrial membrane that
results in cytochrome C release and caspase 3 activation. We
examined whether cytochrome C release into the cytoplasm and
caspase 3 activation were affected by 14-3-3h overexpression by
Western blotting. Cytochrome C release into the cytoplasm was
observed in vector control cells upon rotenone (5 mM) treatment
for 24 hours but was robustly decreased in 14-3-3h cells.
Cytochrome C release in 14-3-3h cells was about 18% of that of
vector control cells (Fig. 3a; p,0.01, Bonferroni’s multiple
comparison test). As shown by Western blotting of whole cell
lysates, rotenone-mediated caspase 3 activation was also reduced
in 14-3-3h cells compared to vector control cells; quantitative
analysis revealed that cleaved caspase 3 levels in 14-3-3h cells was
reduced to 33% of vector control cells (Fig. 3b; p,0.01,
Bonferroni’s multiple comparison test). Therefore, 14-3-3h
overexpression not only reduced Bax activation but also reduced
the activation of signaling events downstream of its activation.
Bax inhibition by alternate means is neuroprotective
If the inhibition of Bax by 14-3-3h is sufficient to mediate 14-3-
3h’s neuroprotective effects, then we predict that inhibition of Bax
through alternative mechanisms should also reduce toxicity in
response to rotenone in M17 cells. To test this, we inhibited Bax
through two methods: 1) pharmacological inhibition with the Bax
inhibitor peptide (BIP) [32], and 2) shRNA-mediated knockdown
of Bax expression. Vector control and 14-3-3h cells were
pretreated with 200 or 500 mM BIP for four hours and then
treated with 1 mM rotenone for 48 hours in the presence of BIP.
Cell death was assayed by lactate dehydrogenase (LDH) release
into the media, and LDH release was normalized to total LDH
release per well, as previously described. BIP showed a reduction
in rotenone toxicity in M17 cells in a dose-dependent manner.
Treatment with 500 mM BIP reduced LDH release to 65% of cells
treated with rotenone only (Fig. 4a; p,0.001, Bonferroni’s
multiple comparison test).
We then examined whether knockdown of Bax by shRNA
would affect the sensitivity of M17 cells to rotenone. M17 cells
were infected with lentivirus containing a shRNA targeting Bax or
with lentivirus containing the pLKO.1 empty vector only. Cells
infected with the Bax shRNA showed knockdown of Bax
expression by Western blotting (Fig. 4b). After incubation with
1 mM rotenone for 48 hours, Bax shRNA cells showed reduced
cell death compared to control cells, as measured by LDH release.
At 1 mM rotenone, Bax knockdown reduced cell death to 54% of
control cells (Fig. 4c; p,0.001, Bonferroni’s multiple comparison
test). The amount of protection with Bax knockdown was
comparable to protection provided by 14-3-3h overexpression
that we have previously observed ([14] and Fig. 5b).
We next tested whether knockdown of Bax in 14-3-3h stable
cells would provide additional protection against rotenone. Both
control stable and 14-3-3h stable cell lines infected with Bax
shRNA showed knockdown of Bax as determined by Western
blotting (Fig. 4d). After incubation with rotenone for 48 hours, 14-
3-3h cells in which Bax expression was eliminated by shRNA
showed additional protection against rotenone compared to 14-3-
3h cells infected with control (pLKO.1 empty vector) virus (Fig. 4e).
Control stable cells infected with Bax shRNA showed less
protection compared to 14-3-3h cells infected with Bax shRNA
(Fig. 4e).
Mutant 14-3-3h that cannot bind Bax is not protective
against rotenone
To test whether the interaction of 14-3-3h with Bax is required
for its neuroprotective effects, we created a mutant 14-3-3h that
shows significantly reduced affinity for Bax. Upon apoptotic
stimuli, caspases can cleave 14-3-3h at Asp 239 in the C-terminal
end that results in a reduction of 14-3-3h’s binding to Bax [16].
Unlike other 14-3-3 ligands, Bax binds to 14-3-3s in a
phosphorylation-independent manner requiring the C-terminal
end of 14-3-3 [16]. Our mutant has a deletion of six amino acids at
the C-terminal end to mimic this caspase cleavage product. After
creating a V5 epitope-tagged deletion mutant, we transfected M17
cells with this mutant construct and selected for stably-transfected
cells.
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PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21720Figure 2. Rotenone-induced Bax activation is reduced in 14-3-3h-overexpressing cells. a) Less Bax translocated to mitochondria in
14-3-3h cells in response to rotenone. After treatment with 5 mM rotenone for 24 hours, vector control and 14-3-3h cell lysates were
subfractionated into cytosolic and mitochondrial fractions and immunoblotted with a polyclonal rabbit antibody against Bax. For each fraction, lanes
for vector control and 14-3-3h cells are from the same gel and exposure time but are separated for clarity with regard to quantification. Bax levels
were normalized to tubulin for the cytosolic fraction or cyclophilin D for the mitochondrial fraction. Bax levels for rotenone-treated cells are shown as
the relative percentage of the corresponding untreated cells. Densitometric quantification included seven separate experiments. Error bars reflect
SEM. *p,0.05, **p,0.01 (one sample t-test). b) Total Bax levels were unchanged with rotenone treatment in either cell line. After
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cipitate with Bax in these stable 14-3-3h mutant cells in contrast to
full-length 14-3-3h(Fig. 5a). We next investigated whether stable
cells overexpressing the mutant 14-3-3h were similarly resistant to
rotenone treatment as were full-length 14-3-3h cells. Control, full-
length 14-3-3h, and mutant 14-3-3h cells were treated with
varying doses of rotenone for 48 hours, and cell death was assayed
by LDH release into the media. While 14-3-3h cells showed
reduction in cell death in response to rotenone treatment, cells
overexpressing the mutant 14-3-3h did not show any protection
against rotenone toxicity (Fig. 5b).
14-3-3h overexpression also protects against disruption
of the mitochondrial membrane potential
Our Bax knockdown experiments implicate additional mecha-
nisms besides Bax inhibition for 14-3-3h’s neuroprotective effects.
Since rotenone can directly inhibit Complex I to disrupt the
mitochondrial membrane potential (Dym), 14-3-3h could modu-
late this effect in a manner independent of Bax inhibition. We
measured the effect of 14-3-3h overexpression on Dym. Changes
in Dym were determined by using the ratiometric fluorescent dye
JC-1. As expected, Dym was reduced with increasing doses of
rotenone in vector control cells. The rotenone-mediated decrease
in Dym was significantly attenuated in 14-3-3h cells (Fig. 6). The
mitochondrial respiratory chain uncoupler, carbonyl cyanide 3-
chlorophenylhydrazone (CCCP) was used as a positive control for
disruption of Dym (Fig. 6).
Discussion
In this study, we have investigated the mechanism by which
14-3-3h is neuroprotective in a cellular PD model. While 14-3-3s
are known to interact with and inhibit many pro-apoptotic factors,
here we demonstrate that inhibition of one such factor in
particular, Bax, is important to 14-3-3h’s protection against
treatment with 5 mM rotenone for 24 hours, whole cell lysates were immunoblotted with an anti-Bax antibody. c) Fewer 14-3-3h cells were
positive for activated Bax upon rotenone treatment. After treatment without (i-iv) or with rotenone (v-viii) for 16 hours, vector control and 14-
3-3h cells were fixed in 2% paraformaldehyde and immunostained with a monoclonal mouse antibody against the active Bax conformation (6A7) and
a goat Alexa 488-conjugated anti-mouse secondary antibody (i, ii, v, vi). Nuclei were stained with Hoechst 33342 (iii, iv, vii, viii). The number of 6A7-
positive cells was quantitated with rater blind to experimental conditions. Error bars reflect SEM. **p,0.01, ***p,0.001 (Bonferroni’s multiple
comparison test). Scale bar =50 mm. d) Rotenone-induced Bax oligomerization was reduced in 14-3-3h cells. Vector control and 14-3-3h
stable cells were treated with 5 mM rotenone for 24 hours. Mitochondrially-enriched fractions were crosslinked and immunoblotted for oligomers
with an anti-Bax antibody. Cyclophilin D served as loading control. Densitometric quantification includes three independent experiments. Error bars
reflect SEM. ***p,0.001 (Bonferroni’s multiple comparison test). n.s. = non-significant.
doi:10.1371/journal.pone.0021720.g002
Figure 3. 14-3-3h overexpression reduces rotenone-induced cytochrome C release and caspase 3 cleavage. a) Vector control and 14-3-
3h cells were treated with 5 mM rotenone for 24 hours, and cytosolic fractions were immunoblotted with a mouse monoclonal antibody against
cytochrome C. Densitometric quantification includes five independent experiments. Tubulin was used as the loading control for Western blots. Error
bars reflect SEM. **p,0.01 (Bonferroni’s multiple comparison test). n.s. = non-significant. b) Vector control and 14-3-3h cells were treated with 5 mM
rotenone for 24 hours, and cell lysates were immunoblotted with a rabbit polyclonal antibody against cleaved caspase 3. Densitometric
quantification includes three independent experiments. Tubulin was used as the loading control for Western blots. Error bars reflect SEM. **p,0.01,
***p,0.001 (Bonferroni’s multiple comparison test). n.s. = non-significant.
doi:10.1371/journal.pone.0021720.g003
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overexpression of 14-3-3h reduced Bax activation and downstream
signaling events, including cytochrome C release and caspase 3
activation. Inhibition of Bax by pharmacological or shRNA
knockdown provided protection against rotenone toxicity, while
14-3-3h mutant that is incapable of binding Bax showed no
protection against rotenone toxicity. These findings suggest that
Bax inhibition is required for 14-3-3h’s effects against rotenone.
However, as 14-3-3h overexpression promotes additional neuro-
protection in the presence of Bax knockdown, additional
mechanisms likely contribute to 14-3-3h’s neuroprotective effects.
In this study, we focused on 14-3-3h as it showed the most
significant protection against cell death in several PD models [14].
As both 14-3-3e and f can also interact with Bax [16,23], it is
possible that the neuroprotective effects of these isoforms seen in
our previous study [14] could also be mediated through Bax
inhibition.
Nomura et al. (2003) have previously shown that 14-3-3h inhibits
Bax by binding directly to Bax at the N- and C-terminal ends of
Bax [16]. This interaction between 14-3-3s and Bax does not
involve the usual phosphorylation binding motifs (RSXpSXP or
RXXXpSXP) that most ligands require for binding to 14-3-3s.
Cleavage of 14-3-3h’s C-terminal end by caspases results in the
release of Bax [16], and we demonstrate that this 14-3-3h cleavage
product cannot protect against rotenone toxicity. The simplest
interpretation of our data is that 14-3-3h directly binds to Bax via
its C-terminal end to induce neuroprotection. However, we cannot
rule out the possibility that 14-3-3h interacts indirectly with Bax by
means of an intermediary ligand.
While our study reveals that inhibition of Bax is key to 14-3-3h’s
neuroprotective effects, it is likely that other mechanisms do
contribute to 14-3-3h’s effects. Knockdown of Bax in M17 cells did
provide comparable protection against rotenone as 14-3-3h
overexpression did, but we found that knockdown of Bax in the
presence of 14-3-3h overexpression provided additional protec-
tion. This finding suggests that the amount of 14-3-3h overex-
pression was likely not sufficient to inhibit all Bax expressed in our
cells. It also suggests that additional mechanisms may also mediate
14-3-3h’s effects, as Bax knockdown in 14-3-3h stable cells was
more protective against rotenone than Bax knockdown in control
stable cells. We did find that 14-3-3h overexpression reduces
disruption of Dym by rotenone, suggesting that 14-3-3h can act
directly or indirectly at the mitochondrial respiratory chain in a
manner that may be independent of Bax.
Given 14-3-3s’ known interactions with other apoptotic factors
[1], 14-3-3h could also inhibit other pro-apoptotic factors to
promote cell survival. We did investigate a potential role for BAD,
another apoptotic factor inhibited by 14-3-3s, but we saw a
comparable increase in BAD phosphorylation and translocation of
BAD to the cytosol upon rotenone treatment in both control and
14-3-3h cells (data not shown). Pro-apoptotic signals typically
promote BAD dephosphorylation, resulting in release from 14-3-3
binding, mitochondrial translocation, and activation of apoptotic
signaling cascades [33]. Since we observed decreased BAD
Figure 4. Bax inhibition through alternative means is protective against rotenone toxicity. a) M17 cells were pretreated with BIP (0, 200,
or 500 mM) for four hours prior to treatment with rotenone at 1 mM. After 48 hours, cell death was assessed by LDH release into the culture media.
LDH release into media was normalized to maximal LDH release for each well. Cells treated with BIP were more resistant to rotenone compared to
untreated cells. Error bars reflect SEM. Results reflect three independent experiments with at least two replicates per experiment. ***p,0.001
(Bonferroni’s multiple comparison test). b) shRNA targeting Bax showed considerable knockdown of Bax protein expression. Naı ¨ve M17 cells were
infected with a pLKO.1 lentiviral construct containing Bax-specific shRNA sequence or with an empty pLKO.1 lentiviral construct (with no shRNA
sequence; C). Infected cells were selected for in the presence of puromycin. Protein lysates from these infected cells were immunoblotted with a
polyclonal antibody against Bax (top blot). Immunoblotting against tubulin (bottom blot) shows comparable protein loading. c) pLKO.1 control or
Bax-shRNA M17 cells were treated with rotenone at varying concentrations for 48 hours. Cell death was assessed by LDH release. Bax-knockdown
cells showed considerable protection against rotenone compared to control cells at all concentrations tested. Error bars reflect SEM. Results reflect
three independent experiments with at least two replicates per experiment. ***p,0.001 (Bonferroni’s multiple comparison test). d) shRNA targeting
Bax also showed knockdown of Bax protein in both empty vector control and 14-3-3h stable cell lines. Control and 14-3-3h stable lines were infected
with an empty pLKO.1 virus (C) or with the Bax-specific shRNA lentivirus. Protein lysates from these cells were immunoblotted with a polyclonal
antibody against Bax and tubulin. e) Empty vector stable and 14-3-3h stable cells infected with either empty pLKO.1 or Bax shRNA viruses were
treated with rotenone at varying concentrations for 48 hours, and cell death was assessed by LDH release. Knockdown of Bax in 14-3-3h stable cells
provided additional reduction of rotenone toxicity. Error bars reflect SEM. Results reflect four independent experiments with at least two replicates
per experiment. *p,0.05, **p,0.01, ***p,0.001 (Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0021720.g004
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mitochondrial translocation in response to rotenone, we concluded
that BAD is unlikely to play a role in our cellular system. Whether
inhibition of other pro-apoptotic factors by 14-3-3h contributes to
its neuroprotective effects, inhibition of Bax is central to 14-3-3h’s
neuroprotection, as disruption of the interaction between 14-3-3h
and Bax abolishes 14-3-3h’s effect.
Accumulating evidence supports the role of 14-3-3s in the
pathogenesis of PD, and direct interactions with several other
proteins implicated in PD has been shown. 14-3-3s have been
demonstrated to colocalize with a-syn in Lewy Bodies and show
increased immunoprecipitation with a-syn in PD brains [4,12]. In
addition, we have previously shown that expression levels of
several 14-3-3 isoforms are reduced in transgenic mice overex-
pressing human wildtype a-syn [13,14]. 14-3-3g can regulate the
ubiquitin ligase activity of parkin, while disease-causing mutations
in parkin disrupt its interaction with 14-3-3h [12]. The interaction
of 14-3-3s with LRRK2 suggests a role for 14-3-3s in regulating
LRRK2 function, especially since some common disease-causing
mutations in LRRK2 can disrupt its interaction with 14-3-3s
[34,35,36].
While we do not directly examine the interaction of 14-3-3h and
Bax in a genetic model of PD, our data presented here has
implications for the pathophysiology of PD. Rotenone is a widely
accepted toxin-based model of PD. Pesticides have been associated
with an increased risk of developing PD [37,38,39,40], and
oxidative stress has long been implicated in the pathogenesis of PD
[41]. Rotenone is a pesticide that causes toxicity in cultured
neuroblastoma cells via inhibition of complex I in mitochondria,
and causes specific loss of nigral neurons in rodents when injected
systemically [42,43,44]. Chronic treatment with rotenone causes
a-syn aggregation in vitro and in vivo [42,43,44]. If increased a-syn
levels observed in PD can cause disruption of 14-3-3 function, we
predict that pro-apoptotic factors normally inhibited by 14-3-3s
could be freed to activate cell death pathways that then contribute
to the neurodegeneration seen in PD. Our data here supports this
hypothesis. In response to rotenone, which induces a-syn
aggregation in M17 cells [14], Bax is activated and cell death
occurs. With overexpression of 14-3-3h, Bax activation is reduced,
resulting in decreased cell death in response to rotenone. In
contrast, overexpression of mutant 14-3-3h which cannot bind Bax
is incapable of preventing rotenone toxicity. The balance of 14-3-
3s and pro-apoptotic factors likely determines the fate of cells in
response to rotenone toxicity. Further examination of this
interaction between Bax and 14-3-3h in other PD models will be
of interest.
Bax has been previously investigated for its potential role in PD.
Bax immunoreactivity is increased in the substantia nigra of PD
brains compared to control [45], and its expression and activation
are induced in cells treated with rotenone and MPP
+ [19,20,22].
In a chronic MPTP mouse model, protein levels of Bax are
increased within days after the last MPTP injection, and
mitochondrial translocation of Bax is observed [21,46]. Bax
knockout mice are resistant to MPTP-induced neurodegeneration
in the substantia nigra [21], while blocking the increase in Bax
Figure 5. 14-3-3h mutant that cannot bind Bax is not protective
against rotenone. a) Lysates from stable cells overexpressing either
full-length 14-3-3h or a C-terminally deleted mutant 14-3-3h (aa1-239)
were immunoprecipitated with a polyclonal rabbit antibody against Bax
and then immunoblotted with a monoclonal mouse antibody against
V5. Blot was reprobed with anti-Bax antibody to verify Bax pulldown
(bottom blot). Lysate lanes on right in the Bax blot are shown at a
different exposure time than the immunoprecipitant lanes from the
same gel. Considerably much less mutant 14-3-3h was immunoprecip-
itated with Bax compared to full-length 14-3-3h. b) Vector control, full-
length 14-3-3h, or mutant 14-3-3h cells were treated with rotenone for
48 hours. Cell death was assessed by LDH release. While full-length 14-
3-3h cells showed decreased cell death in response to rotenone, cells
overexpressing mutant 14-3-3h showed no protection against rotenone
compared to vector control cells. Error bars reflect SEM. Results reflect
three independent experiments with at least two replicates per
experiment. ***p,0.001 (Bonferroni’s multiple comparison test). n.s.
= non-significant.
doi:10.1371/journal.pone.0021720.g005
Figure 6. 14-3-3h overexpression reduces rotenone-induced
disruption of mitochondrial membrane potential. Vector control
and 14-3-3h cells were treated with varying doses of rotenone or 10 mM
carbonyl cyanide 3-chlorophenylhydrazone (CCCP), a mitochondrial
toxin, for 24 hours. Mitochondrial membrane potential was assayed by
the JC-1 assay. Ratio of aggregated JC-1 (red) to monomer JC-1 (green)
for each condition was normalized to that ratio for the corresponding
untreated cells. Results reflect three independent experiments with
three replicates per experiment. Error bars reflect SEM. **p,0.01,
***p,0.001 (Bonferroni’s multiple comparison test).
doi:10.1371/journal.pone.0021720.g006
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can also reduce dopaminergic cell loss in MPTP-treated mice [47].
Our studies here show that 14-3-3h is neuroprotective in a PD
model through its inhibition of Bax. We show that M17 cells
overexpressing 14-3-3h show reduced Bax activation, signaling
downstream of Bax, and cell death, while a mutant 14-3-3h that
cannot interact with Bax fails to reduce rotenone toxicity. As Bax
activation is important to PD pathogenesis, 14-3-3h could serve as
a potential target for the development of new PD therapeutics.
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